M. Scott Harris

Dr. M. Scott Harris


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2024 in Journal of Hepatology
Verified
Journal Article
Open access
SHStephen A. Harrison
Stephen A. Harrison
SBSarah K. Browne
Sarah K. Browne
JSJohn J. Suschak
John J. Suschak
STShaheen Tomah
Shaheen Tomah
JGJulio A. Gutierrez
Julio A. Gutierrez
MHM. Scott Harris
M. Scott Harris
This was a randomized, double-blind, placebo-controlled study to assess the effects of pemvidutide, a glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist, on liver fat content (LFC) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). Patients with a BMI ≥28.0 kg/m2 and LFC ≥10% by magnetic resonance imaging-proton density fat fraction were randomized 1:1:1:1 to pemvidutide at 1.2 mg, 1.8 mg, or 2.4 mg, or placebo administered subcutaneously once weekly for 12 weeks. Participants were stratified according to a diagnosis of type 2 diabetes mellitus. The primary efficacy endpoint was relative reduction (%) from baseline in LFC after 12 weeks of treatment. Ninety-four patients were randomized and dosed. Median baseline BMI and LFC across the study population were 36.2 kg/m2 and 20.6%; 29% of patients had type 2 diabetes mellitus. At week 12, relative reductions in LFC from baseline were 46.6% (95% CI -63.7 to -29.6), 68.5% (95% CI -84.4 to -52.5), and 57.1% (95% CI -76.1 to -38.1) for the pemvidutide 1.2 mg, 1.8 mg, and 2.4 mg groups, respectively, vs. 4.4% (95% CI -20.2 to 11.3) for the placebo group (p <0.001 vs. placebo, all treatment groups), with 94.4% and 72.2% of patients achieving 30% and 50% reductions in LFC and 55.6% achieving normalization (≤5% LFC) at the 1.8 mg dose. Maximal responses for weight loss (-4.3%; p <0.001), alanine aminotransferase (-13.8 IU/L; p = 0.029), and corrected cT1 (-75.9 ms; p = 0.002) were all observed at the 1.8 mg dose. Pemvidutide was well-tolerated at all doses with no severe or serious adverse events. In patients with MASLD, weekly pemvidutide treatment yielded significant reductions in LFC, markers of hepatic inflammation, and body weight compared to placebo. Metabolic dysfunction-associated steatotic liver disease, and its progressive form steatohepatitis, are strongly associated with overweight/obesity and it is believed that the excess liver fat associated with obesity is an important driver of these diseases. Glucagon-like peptide-1 receptor (GLP-1R) agonists elicit weight loss through centrally and peripherally mediated effects on appetite. Unlike GLP-1R agonists, glucagon receptor agonists act directly on the liver to stimulate fatty acid oxidation and inhibit lipogenesis, potentially providing a more potent mechanism for liver fat content reduction than weight loss alone. This study demonstrated the ability of once-weekly treatment with pemvidutide, a dual GLP-1R/glucagon receptor agonist, to significantly reduce liver fat content, hepatic inflammatory activity, and body weight, suggesting that pemvidutide may be an effective treatment for both metabolic dysfunction-associated steatohepatitis and obesity. NCT05006885.

28 January 2016 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
PDF file
MHM. Scott Harris
M. Scott Harris
DHDeborah Hartman
Deborah Hartman
BLBrenda R. Lemos
Brenda R. Lemos
EEEmma C. Erlich
Emma C. Erlich
SSSharon Spence
Sharon Spence
BFBarbara S. Fox
Barbara S. Fox
BACKGROUND AND AIMS: AVX-470 is an oral, polyclonal bovine-derived anti-TNF antibody in development for treatment of IBD. AVX-470 neutralizes TNF locally in the gastrointestinal tract, minimizing systemic exposure. This was a double-blind, placebo-controlled, first-in-human trial designed to assess the safety, pharmacokinetics, immunogenicity and preliminary efficacy of 4 weeks of AVX-470 in patients with active ulcerative colitis (UC). METHODS: 37 patients with active UC were randomized and 36 received AVX-470 (0.2, 1.6 or 3.5 g/day) or placebo over 4 weeks. Endoscopic activity was assessed by colonoscopy pre- and post-treatment. The primary endpoint was safety. Secondary endpoints included pharmacokinetics and immunogenicity. Clinical and endoscopic response and remission were assessed as exploratory endpoints. RESULTS: Thirty-three (92%) patients completed treatment and follow up. The incidence of adverse events was similar across treatment groups, and no allergic reactions or opportunistic infections were reported. AVX-470 therapy did not induce human anti-bovine antibodies (HABA). Bovine Ig with TNF binding capacity was detected in stool, while bovine Ig levels in serum were low. 25.9% of patients across all AVX-470 doses achieved clinical response compared to 11.1% on placebo, with greatest improvements in the 3.5 g/day group associated with proximal colon endoscopic improvement and reductions in serum CRP and IL-6. CONCLUSIONS: AVX-470 was safe and well tolerated in this first-in-human trial of UC, with efficacy trends for clinical, endoscopic, and biomarker endpoints at the 3.5 g/day highest dose group. Results suggest benefit of an orally delivered locally active agent in moderate-severe UC.

1 December 2019 in Gastroenterology
Verified
Journal Article
Closed access
MHM. Scott Harris
M. Scott Harris
JWJolanta Wichary
Jolanta Wichary
MZMatt Zadnik
Matt Zadnik
WRWalter Reinisch
Walter Reinisch

6 May 2019 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
DHDaren K. Heyland
Daren K. Heyland
AZArthur R. H. van Zanten
Arthur R. H. van Zanten
TGTeodoro Grau-Carmona
Teodoro Grau-Carmona
DEDavid Evans
David Evans
ABAlbertus Beishuizen
Albertus Beishuizen
JPJuan Posadas
Juan Posadas

18 June 2025 in JHEP Reports
Verified
Journal Article
Open access
SBSarah K. Browne
Sarah K. Browne
JSJohn J. Suschak
John J. Suschak
STShaheen Tomah
Shaheen Tomah
JGJulio A. Gutierrez
Julio A. Gutierrez
JYJay Yang
Jay Yang
MHM. Scott Harris
M. Scott Harris
This was a double-blind 12-week extension of a randomized, placebo-controlled, 12-week trial of pemvidutide, a glucagon-like peptide-1/glucagon dual receptor agonist, in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). Completers of a double-blind trial of pemvidutide in MASLD, who were previously randomized 1:1:1:1 to pemvidutide at 1.2 mg, 1.8 mg, or 2.4 mg, or placebo administered subcutaneously once weekly for 12 weeks, were offered an additional 12 weeks of treatment at their originally assigned dose for a total of 24 weeks of treatment. Participants were stratified by the presence or absence of type 2 diabetes mellitus (T2DM). The primary efficacy endpoint was relative reduction (%) from baseline in liver fat content by magnetic resonance imaging-proton density fat fraction after 24 weeks of treatment. There were 64 participants in the extension trial. Baseline mean values for BMI and liver fat content were 36.7 kg/m2 and 22.2%; 26.6% of participants had T2DM. After 24 weeks of treatment, pemvidutide achieved relative reductions in liver fat content from baseline of 56.3%, 75.2%, and 76.4% for the pemvidutide 1.2 mg, 1.8 mg, and 2.4 mg groups respectively, vs. 14.0% for placebo (p <0.001 vs. placebo, all treatment groups), with 84.6% of participants achieving 50% reductions in liver fat content and 53.8% achieving normalization (≤5% liver fat content) at the 1.8 mg dose. Body weight was also reduced by 6.2% (p <0.001 vs. placebo) over 24 weeks of treatment. Pemvidutide was well-tolerated at all doses, with low incidences of side effects. In individuals with MASLD, 24 weeks of pemvidutide treatment resulted in significant reductions in liver fat content and body weight that further improved upon the effects observed at 12 weeks. Overweight and obesity are strongly associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASH), as the excess liver fat associated with obesity is a known driver of these conditions. Glucagon-like peptide-1 receptor (GLP-1R) agonists elicit weight loss through centrally and peripherally mediated effects on appetite, whereas G-coupled glucagon receptor (GCGR) agonists act directly on the liver to stimulate fatty acid oxidation and inhibit lipogenesis, providing a more potent mechanism for reducing liver fat content than weight loss alone. We previously showed that once-weekly treatment with pemvidutide, a dual GLP-1R/GCGR agonist, significantly reduced liver fat content, hepatic inflammatory activity, and body weight over 12 weeks. The current trial demonstrates that continued treatment with pemvidutide further improves these clinical markers of MASH. The study is registered at ClinicalTrials.gov (NCT05292911).

3 February 2020 in Neurogastroenterology & Motility
Verified
Journal Article
Open access
PDF file
JJJoyce James
Joyce James
SMStuart Mair
Stuart Mair
WDWalter Doll
Walter Doll
ESErik Sandefer
Erik Sandefer
DWDavid Wurtman
David Wurtman
MHM. Scott Harris
M. Scott Harris
Background: Ulimorelin, a small molecule ghrelin agonist and prokinetic agent, was effective in animal models of gastroparesis and delayed transit. However, employing once daily administration, it failed in clinical trials of postoperative ileus (POI), a condition in which colonic motility recovers last. The aim of this study was to evaluate drug dosing and regional differences in drug activity between stomach and colon.Methods: Gastric emptying was assessed by scintigraphy in healthy adults at single doses of 600‐1200 µg kg−1 and multiple doses of 80‐600 µg kg−1 Q8H for 7 days. Colonic motility was assessed by 7‐region scintigraphic analysis at a dose of 600 µg kg−1 for 2 days. The primary endpoints were percent change in time to 50% (∆t50) liquid gastric emptying on Days 1, 4, and 6 and the geometric mean center of colonic transit at 24 hours (GC24). Plasma concentrations of free and total ulimorelin were measured for pharmacokinetic and exposure‐response modeling.Key Results: Ulimorelin 150‐600 µg kg−1 every 8 hours resulted in statistically significant improvements (∆t50 = 23% to 46% (P < .05)) in gastric emptying from baseline that were sustained through Day 6. However, no effects on GC24 were observed. Pharmacokinetic analyses suggested that the free concentrations of ulimorelin achieved in POI trials and dosing frequency may have been inadequate.Conclusions and Inferences: Ulimorelin is a potent gastric prokinetic but lacks evidence of activity in the human colon, pointing to the stomach as the predominant site of action of ghrelin in humans; ClinicalTrials.gov NCT02993055.